New drug duo shows promise for hard-to-treat ovarian cancer in japanese women

NCT ID NCT06682572

Ongoing Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 21 times

Summary

This study tests two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum chemotherapy. The goal is to see if the combination shrinks tumors and how safe it is. Participants must have measurable disease and adequate organ function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Aichi Cancer Center Hospital

Nagoya, Aichi-ken, 464-8681, Japan
Jikei University Hospital

Minato, Tokyo, 105-0003, Japan
Kurume University Hospital

Kurume, Fukuoka, 830-0011, Japan
Mie University Hospital

Tsu, Mie-ken, 514-8507, Japan
Tohoku University Hospital

Sendai, Miyagi, 980-8574, Japan

Conditions

The condition(s) this trial relates to.

borderline ovarian serous tumor ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOW GRADE SEROUS OVARIAN CANCER LOW GRADE SEROUS OVARIAN CANCER OVARIAN CANCER